GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vireo Growth Inc (OTCPK:VREOF) » Definitions » Cash Conversion Cycle

VREOF (Vireo Growth) Cash Conversion Cycle : 139.38 (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Vireo Growth Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Vireo Growth's Days Sales Outstanding for the three months ended in Jun. 2024 was 6.92.
Vireo Growth's Days Inventory for the three months ended in Jun. 2024 was 155.74.
Vireo Growth's Days Payable for the three months ended in Jun. 2024 was 23.28.
Therefore, Vireo Growth's Cash Conversion Cycle (CCC) for the three months ended in Jun. 2024 was 139.38.


Vireo Growth Cash Conversion Cycle Historical Data

The historical data trend for Vireo Growth's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vireo Growth Cash Conversion Cycle Chart

Vireo Growth Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 238.14 148.11 167.42 163.23 157.34

Vireo Growth Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 169.23 146.45 140.29 141.72 139.38

Competitive Comparison of Vireo Growth's Cash Conversion Cycle

For the Drug Manufacturers - Specialty & Generic subindustry, Vireo Growth's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vireo Growth's Cash Conversion Cycle Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vireo Growth's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Vireo Growth's Cash Conversion Cycle falls into.



Vireo Growth Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Vireo Growth's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=7.62+164.95-15.23
=157.34

Vireo Growth's Cash Conversion Cycle for the quarter that ended in Jun. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=6.92+155.74-23.28
=139.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vireo Growth  (OTCPK:VREOF) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Vireo Growth Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Vireo Growth's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Vireo Growth Business Description

Traded in Other Exchanges
Address
207 South 9th Street, Minneapolis, Minneapolis, MN, USA, 55402
Vireo Growth Inc is a cannabis company whose mission is to provide safe access, quality products, and value to its customers while supporting its local communities through active participation and restorative justice programs.
Executives
Chicago Atlantic Credit Opportunities, Llc 10 percent owner 420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Manager, Llc 10 percent owner 420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Gp Holdings, Llc 10 percent owner 420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Group, Lp 10 percent owner 420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Group Gp, Llc 10 percent owner 420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Advisers, Llc 10 percent owner 420 NORTH WABASH AVENUE, SUITE 500, CHICAGO IL 60611
Joshua Rosen director 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Victor E. Mancebo director C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Christian Gonzales Ocasio officer: Chief Operating Officer C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Amber Holly Shimpa director, officer: Chief Administrative Officer C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Patrick Peters officer: EVP of Retail C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
J Michael Schroeder officer: General Counsel & CCO 3680 VICTORA STREET N, SHOREVIEW MN 55126
John Andrew Heller officer: Chief Financial Officer C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Ross Michael Hussey director C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Judd Theodore Nordquist director C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402